Hospital
Olympia Health Care LLC
Olympia Health Care LLC was paid $3.92M by Medicaid between Jan 2018 and Mar 2021, across 131 billing codes. Its largest line is 0450, Emergency room services — 25% of everything it billed.
33Billing provider infoOLYMPIA HEALTH CARE LLC
LOS ANGELES, CA 90036
LOS ANGELES, CA 90036
33aNPI1245371343assigned 02/09/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.92M
24GClaims153,819
24DCodes billed131
24AFirst – last monthJan 2018 – Mar 2021
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#237 of 410
Median peer was paid$6.90M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 59,240 | $1.57M | |
| 2019 | 48,517 | $1.42M | |
| 2020 | 39,664 | $809K | |
| 2021 | 6,398 | $118K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 25% | 21,334 | 19,132 | $960K |
| 0250 | 8.7% | 4,956 | 3,506 | $342K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 7.8% | 4,270 | 3,643 | $305K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.6% | 1,584 | 1,459 | $179K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.2% | 3,804 | 3,508 | $163K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 1,502 | 1,435 | $126K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 637 | 608 | $125K |
| J3490 | Unclassified drugs | 2.5% | 6,784 | 5,031 | $98K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.2% | 2,379 | 2,203 | $85K |
| 80053 | Comprehensive metabolic panel | 2.0% | 7,376 | 6,707 | $80K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.9% | 1,676 | 1,559 | $76K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.9% | 1,021 | 899 | $74K |
119 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 4,077 | $73K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 2,853 | $70K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 3,040 | $65K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 957 | $60K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 623 | $54K |
| 0300 | 1.4% | 165 | $54K | |
| 71045 | Radiologic examination, chest; single view | 1.2% | 4,280 | $47K |
| 0258 | 1.2% | 455 | $47K | |
| 0270 | 1.2% | 1,795 | $47K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 7,872 | $47K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 5,594 | $45K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 717 | $36K |
| 84484 | <1% | 2,875 | $36K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 592 | $33K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 629 | $30K |
| 81003 | <1% | 6,739 | $26K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 761 | $25K |
| 83880 | <1% | 1,169 | $23K | |
| 81025 | <1% | 3,949 | $23K | |
| Z7502 | <1% | 614 | $23K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,283 | $22K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,212 | $22K |
| 0370 | <1% | 45 | $22K | |
| 83690 | <1% | 3,409 | $20K | |
| 99199 | Unlisted special service, procedure or report | <1% | 488 | $19K |
| 0259 | <1% | 1,545 | $18K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,270 | $17K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,255 | $14K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 364 | $14K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,014 | $12K |
| 73562 | <1% | 383 | $12K | |
| 0637 | <1% | 1,437 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,554 | $11K |
| 0324 | <1% | 104 | $11K | |
| 99221 | <1% | 405 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,270 | $10K |
| 0301 | <1% | 20 | $8K | |
| 82550 | <1% | 1,590 | $8K | |
| 90715 | <1% | 292 | $8K | |
| 85730 | <1% | 1,777 | $8K | |
| 0305 | <1% | 16 | $8K | |
| 85610 | <1% | 1,833 | $7K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 69 | $7K |
| 73630 | <1% | 303 | $7K | |
| 82553 | <1% | 807 | $7K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 800 | $6K |
| 86710 | <1% | 446 | $5K | |
| 73130 | <1% | 241 | $5K | |
| 94664 | <1% | 334 | $5K | |
| 0710 | <1% | 53 | $5K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 95 | $5K |
| 84702 | <1% | 366 | $4K | |
| 87040 | <1% | 329 | $4K | |
| 73030 | <1% | 187 | $4K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 248 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 607 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 235 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 713 | $4K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 78 | $3K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 42 | $3K |
| 73610 | <1% | 171 | $3K | |
| 83605 | <1% | 395 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 63 | $3K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 77 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 676 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 58 | $2K |
| 87181 | <1% | 788 | $2K | |
| 0730 | <1% | 13 | $2K | |
| 81001 | <1% | 564 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 519 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 336 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 97 | $2K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 24 | $2K |
| 0272 | <1% | 20 | $2K | |
| 86850 | <1% | 512 | $2K | |
| 74018 | <1% | 105 | $2K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 169 | $1K |
| A9270 | Non-covered item or service | <1% | 281 | $1K |
| 86901 | <1% | 615 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 307 | $1K |
| 70486 | <1% | 12 | $1K | |
| 86900 | <1% | 613 | $1K | |
| 82248 | <1% | 345 | $1K | |
| 82962 | <1% | 466 | $1K | |
| 73110 | <1% | 75 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 108 | $1K |
| 80329 | <1% | 261 | $1K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 30 | $1K |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 80 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 171 | $1K |
| 83735 | <1% | 203 | $1K | |
| 85379 | <1% | 121 | $958.49 | |
| 85007 | <1% | 360 | $870.32 | |
| 96376 | <1% | 114 | $835.39 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 14 | $698.90 |
| S0028 | Injection, famotidine, 20 mg | <1% | 308 | $640.99 |
| 0636 | <1% | 71 | $632.91 | |
| A4649 | Surgical supply; miscellaneous | <1% | 862 | $548.89 |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12 | $475.00 |
| 72020 | <1% | 24 | $374.26 | |
| 0510 | <1% | 12 | $349.67 | |
| 86140 | <1% | 81 | $320.79 | |
| 71010 | <1% | 26 | $300.36 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $299.14 |
| 0260 | <1% | 21 | $299.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 28 | $218.93 |
| Z7610 | <1% | 14 | $197.96 | |
| J2704 | Injection, propofol, 10 mg | <1% | 26 | $143.54 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 28 | $130.07 |
| J1815 | Injection, insulin, per 5 units | <1% | 13 | $97.64 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 13 | $83.90 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 15 | $63.69 |
| 85651 | <1% | 28 | $58.50 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 16 | $47.22 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15 | $39.35 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 80 | $37.66 |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 91 | $0.00 |
| 90834 | Psychotherapy session, about 45 minutes | 0% | 324 | $0.00 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 0% | 3,338 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, MATT (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Smile Dental LLC | Russellville, AR | $608K |
| Santo Domingo Tribe | Santo Domingo Pueblo, NM | $606K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.